In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen reports. One participant lost 22% of her weight in nine months, substantially faster than the rate seen with approved GLP-1 drugs like Wegovy or Zepbound, and her weight dropped so much that researchers reduced her dose of the treatment, called retatrutide, Chen writes.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly files automatic mixed securities shelf
- S&P 500 Jumps Ahead of Fed Meeting Minutes
- Eli Lilly & Co: Promising Growth Driven by Innovative Pipeline and Market-Leading Weight-Loss Treatments
- Lone Pine Capital takes new position in Eli Lilly, exits UnitedHealth stake
- Tiger Global buys PDD, exits ZoomInfo in Q4